登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《JMV，2月28日，Clinical characteristics of 50466 hospitalized patients with 2019‐nCoV infection》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-01

  • Clinical characteristics of 50466 hospitalized patients with 2019‐nCoV infection

    Pengfei Sun MD Shuyan Qie MD Zongjan Liu MD Jizhen Ren MD Kun Li MD Jianing Xi MD

    First published:28 February 2020 https://doi.org/10.1002/jmv.25735

    Abstract

    Objective

    We aim to summarize reliable evidences of evidence‐based medicine for the treatment and prevention of the 2019 novel coronavirus (2019‐nCoV) by analyzing all the published studies on the clinical characteristics of patients with 2019‐nCoV.

    Methods

    PubMed, Cochrane Library, Embase, and other databases were searched. Several studies on the clinical characteristics of 2019‐nCoV infection were collected for Meta‐analysis.

  • 原文来源：https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25735
13浏览量
原文链接
相关报告

  • 《MedRxiv，2月23日，Clinical characteristics of 50404 patients with 2019-nCoV infection》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-02-24
    • Clinical characteristics of 50404 patients with 2019-nCoV infection Pengfei Sun, Shuyan Qie, Zongjan Liu, Jizhen Ren, Jianing Jianing Xi doi: https://doi.org/10.1101/2020.02.18.20024539 Abstract Objective: To provide reliable evidence of evidence-based medicine for the treatment and prevention of the 2019 novel coronavirus(2019-nCoV) by analyzing all the published studies on the clinical characteristics of patients with 2019-nCoV. Methods: PubMed,Cochrane Library,Embase and other databases were searched. Some studies on the clinical characteristics of 2019-nCoV infection were collected for Meta-analysis .Results: 9 studies were included in Meta-analysis, including a total of 50404 patients with 2019-nCoV infection.According to Meta-analysis, among the clinical characteristics of patients with 2019-nCoV infection, the incidence of fever is 90.9% , the incidence of cough is 70.8%, and the incidence of muscle soreness or fatigue is 41%. The incidence of acute respiratory distress syndrome (ARDS) was 14.8%, the incidence of abnormal chest CT was 95.6%, the proportion of severe cases in all infected cases was 21.3%, and the mortality rate of patients with 2019-nCoV infection was 4.8%. Conclusion: Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of them have abnormal chest CT examination.Some people have muscle soreness or fatigue, ARDS. Diarrhea, hemoptysis, headache, sore throat, shock and other symptoms only occur in a small number of patients.The mortality rate of patients with 2019-nCoV infection was lower than that of Severe Acute Respiratory Syndrome (SRAS) and Middle East Respiratory Syndrome (MERS). *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    98浏览量
    原文链接

  • 《JMV，2月28日，Clinical trial analysis of 2019‐nCoV therapy registered in China》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-01
    • Clinical trial analysis of 2019‐nCoV therapy registered in China Qi Zhang Yakun Wang Changsong Qi Lin Shen Jian Li First published:28 February 2020 https://doi.org/10.1002/jmv.25733 Abstract So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than one hundred clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine and other western drugs, while Chinese medicine researches accounted for half of studies. Most of the trials were initiated by investigators and the study period would last for one to eleven months. The primary endpoints included symptom improvement and virus nucleic acid turning negative, but the optimal endpoint has not been determined. Although the final results of studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for drug treatment. Compared with that of during SARS period in 2003, China have the stronger capability to carry out clinical trials of new drugs in emergency period.
    9浏览量
    原文链接